FXR activation in both the liver and intestines has been shown to inhibit hepatic lipogenesis, improve insulin sensitivity, and enhance energy expenditure, ultimately contributing to the mitigation of obesity risk. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.